Lol … if the only question was the addition of HA then it would have been unethical to include the placebo arm.
You do make a nice illustration of how the cognitive bias operates that I hadn’t spotted before in a three arm trial.
The intervention is assumed to work. And both interventions are assumed to create benefit for every participant in the intervention arms. So the only question as you say is the degree to benefit; good or very good.
It is powerful … and hence why the design even if inefficient is cost-effective.
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment, page-149
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $4.468M | 3.789M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 24679 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 50767 | 12 |
View Market Depth
| Last trade - 14.16pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |